Consistent with the in vitro experiments, IGF2BP3 downregulation reduced glioma survival in wild-type mice, as evidenced by decreased tumor size (Fig. 1f–h), increased survival time (Fig. 1i), and decreased neutrophil infiltration (CD66b + , MPO) and NETosis (H3cit + ) (Fig. 1j–m). The gene discussed is IGF2BP3; the disease is central nervous system cancer.